AZT (zidovudine) + IFN-α — continuous, dose-adjusted

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ZIDOVUDINE` `DRUG-INTERFERON-ALPHA`

ID	`REG-AZT-IFN-A`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. AZT inhibits HTLV-1 reverse transcriptase; IFN — immune modulation + apoptosis induction. PEG-IFN can substitute for standard IFN — easier dosing (weekly). Not for acute / lymphoma type.

Used By

Algorithms

ALGO-ATLL-1L - ALGO-ATLL-1L

Contraindications

CI-PSYCH-DECOMPENSATED-FOR-INTERFERON - CI-PSYCH-DECOMPENSATED-FOR-INTERFERON

Indication

IND-ATLL-1L-INDOLENT-AZT-IFN - IND-ATLL-1L-INDOLENT-AZT-IFN

Supportive Care

SUP-PSYCH-MONITORING-IFN - Neuropsychiatric monitoring during interferon-α therapy